Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?

@article{Ferdinand2008FixeddoseID,
  title={Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?},
  author={Keith C Ferdinand},
  journal={The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics},
  year={2008},
  volume={36 3},
  pages={458-63}
}
Race is not a scientific category, but African Americans have increased prevalence and severity of heart failure. The African American Heart Failure trial showed the benefit of a combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (an antioxidant). Future research may unmask the reason for cardiovascular differences in therapy. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…